Palisades Investment Partners added 137,768 shares of Travere Therapeutics, valued at $5.26 million based on quarterly average price. The position represents 1.99% of their assets under management but is not among their top five holdings. The investment firm initiated this new position based on a recent SEC filing.

Travere Therapeutics, a biotechnology company, saw its shares rise to $27.87 on January 19, 2026, reflecting a 50.89% increase over the past year. The company focuses on rare disease therapies, generating revenue from approved products like Chenodal and Cholbam. Their revenue stood at $435.83 million, with a market cap of $2.46 billion.

The purchase of Travere Therapeutics by Palisades Investment Partners reflects a bullish outlook due to the company’s strong performance. Travere’s revenue grew significantly, with sales of FILSPARI rising 155%. The stock hit a 52-week high of $42.13 in December, driven by positive news on FDA review for FILSPARI.

Travere Therapeutics is positioned for further growth, especially if FILSPARI gains expanded FDA approval. This strategic move by Palisades Investment Partners indicates confidence in Travere’s potential. The company’s focus on rare diseases and innovative treatments aligns with market demand and growth opportunities.

Read more at Yahoo Finance: Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?